Searchable abstracts of presentations at key conferences in endocrinology

ea0029p143 | Bone & Osteoporosis | ICEECE2012

Glucocorticoid - treatment in the adrogenital syndrome due to deficit of 21-hydroxylase: long-term bone side effects

Camozzi V. , Scaroni C. , De Toni P. , Albiger N. , Zaninotto M. , Mantero F. , Luisetto G.

The purpose of this study was to compare bone mineral density (BMD) and bone metabolism in patients suffering from adrogenital syndrome due to deficit of 21-hydroxylase with those of a group of healthy subjects. A longitudinal follow-up was also carried out in a subgroup of patients.Thirty-eight patients 19-47 years old were compared with a group of healthy, age- and sex-matched controls. Sodium, potassium, calcium, phosphorus, parathyroid hormone (PTH),...